Alkem Laboratories Share Price Falls Over 2% After Q2 FY27 Earnings Results: Total Income Up 14.2% YoY

Alkem Laboratories Limited's Board of Directors approved the unaudited consolidated financial results for the quarter and half year ended September 30, 2026, on November 12, 2026, as per the exchange filings.  

For Q2 FY27 total income increased 14.2% year on year to ₹4,686.20 crore, while net profit stood at ₹667.13 crore. 

Alkem Laboratories Q2 and H1 FY27 Financial Performance 

During Q2 FY27, Alkem Laboratories recorded total income of ₹4,686.20 crore, up from ₹4,104.68 crore a year ago and 20.4% higher than ₹3,892.90 crore in the June 2026 quarter, with revenue from operations rising 13.8% to ₹4,551.99 crore and EBITDA reaching ₹1,025.2 crore at a 22.5% margin.  

Net profit declined 14.4% year on year to ₹667.13 crore from ₹779.11 crore, though it increased 28.1% over ₹520.98 crore in Q1 FY27, with owner attributable profit reaching ₹675.34 crore.  

For H1 FY27, total income climbed 12.7% year on year to ₹8,579.10 crore from ₹7,612.31 crore, revenue reached ₹8,292.14 crore across Pharmaceuticals (₹8,001.24 crore), Biotech (₹249.65 crore), and MedTech (₹140.79 crore) before ₹99.54 crore inter segment eliminations, and net profit stood at ₹1,188.11 crore, down 17.9% from ₹1,447.02 crore.  

For FY26, total income stood at ₹15,295.62 crore and net profit was ₹2,351.16 crore. 

Segment Operations, Balance Sheet and Occlutech Acquisition 

In Q2 FY27, domestic sales grew 9.5% year on year to ₹3,027.5 crore, accounting for 68% of total sales, while US sales rose 2.4% to ₹783.0 crore across 170 approved ANDAs, non US international sales climbed 58% to ₹671.0 crore, Biotech posted ₹70.4 crore, and MedTech delivered ₹133.1 crore.  

As of September 30, 2026, consolidated total assets stood at ₹23,059.64 crore, total equity reached ₹15,689.0 crore, net cash stood at ₹4,905.4 crore, and H1 operating cash flow totalled ₹1,044.58 crore.  

On July 16, 2026, subsidiary Alkem Medtech acquired a 55% stake in Occlutech Holding AG for EUR 9,78,00,000 (approximately ₹1,079.76 crore), recognising ₹703.6 crore in goodwill alongside a ₹35.0 crore exceptional recovery.  

The company welcomed Dr. Amrut Naik as CEO, cleared an FDA inspection at Mandva API with 0 observations while Daman underwent OAI remediation, and held ₹61,740 crore market capitalisation with 49.7% promoter ownership. 

Read More: Kalyan Jewellers Share Price Gains Over 9% Post Q2 FY27 Earnings Results: Total Income Up 31.5% YoY! 

Alkem Laboratories Share Price Performance  

As of November 12, 2026, at 3:20 PM, Alkem Laboratories share price on NSE was trading at ₹5,300.00, down by 2.72% from the previous closing price. 

Conclusion 

Alkem Laboratories posted Q2 FY27 total income of ₹4,686.20 crore, up 14.2%, and net profit of ₹667.13 crore, down 14.4% year on year, while H1 FY27 total income reached ₹8,579.10 crore, net profit stood at ₹1,188.11 crore, and consolidated assets reached ₹23,059.64 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.